MIND-4 exhibits neuroprotective activity by inhibiting the deacetylase SIRT2 and inducing the activity of nuclear factor erythroid 2-related factor 2 (NRF2) in a SIRT2-independent manner; it activates NRF2 in both neuronal and non-neuronal cells, reduces the production of reactive oxygen and nitrogen species, and represents a promising multi-target agent for the development of therapeutics against Huntington’s disease (HD) and related disorders.